Completed NA INTERVENTIONAL 1-arm NCT01658150

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade

Sponsor: Brain & Behavior Research Foundation

Conditions Schizoaffective Disorder Schizophrenia

Interventions isradipine

Updated 8 times since 2017 Last updated: Nov 9, 2018 Started: Sep 30, 2012 Primary completion: Jan 2, 2018 Completion: Jan 2, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01658150, this NA trial focuses on Schizoaffective Disorder and Schizophrenia and remains completed. Sponsored by Brain & Behavior Research Foundation, it has been updated 8 times since 2012, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jan 2019 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Jan 2019 [monthly]

Completed NA

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed NA

Status: Recruiting → Completed
Feb 2017 — Apr 2018 [monthly]

Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Recruiting NA

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brain & Behavior Research Foundation
Icahn School of Medicine at Mount Sinai

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States